Regarding the mechanism of action and clinical use of antiparkinsonian drugs, all of the following statements are correct EXCEPT:

Explanation

## Analysis of Antiparkinsonian Drug Mechanisms ### Correct Statements (Options 0, 1, 3) **Option 0: Levodopa Pharmacokinetics** - Levodopa is the prodrug that crosses the BBB via LAT (large neutral amino acid transporter type 1) - Converted to dopamine by aromatic amino acid decarboxylase (AADC) in the brain - This is why it is preferred over dopamine itself (dopamine cannot cross BBB) - Always given with carbidopa or benserazide (peripheral AADC inhibitors) to reduce peripheral conversion **Option 1: Bromocriptine Profile** - D2 receptor agonist (ergot-derived) - Can be used as monotherapy in early PD, particularly in younger patients - Ergot alkaloid structure is correct — causes vasoconstriction risk - ✓ This statement is entirely correct **Option 3: Trihexyphenidyl Efficacy** - Anticholinergic agent most effective for **tremor and rigidity** - Has minimal effect on bradykinesia (hypokinesia) - This is a well-established clinical limitation - ✓ This statement is correct ### Incorrect Statement (Option 2: Selegiline) **Key Point:** Selegiline irreversibly inhibits **MAO-B**, NOT MAO-A. - **MAO-B** is the predominant form in the basal ganglia and metabolizes dopamine - **MAO-A** is found mainly in the GI tract and metabolizes noradrenaline/serotonin - Inhibiting MAO-A would cause the "cheese effect" (tyramine interaction) — a major safety concern - Selegiline's selectivity for MAO-B at therapeutic doses avoids this - While selegiline is used as adjunctive therapy in advanced PD, the mechanism stated is **factually wrong** **High-Yield:** The distinction between MAO-A and MAO-B selectivity is a **frequent NEET PG trap**. Selegiline = MAO-B inhibitor. Phenelzine/tranylcypromine = MAO-A inhibitors (non-selective). ### Clinical Correlation Table | Drug Class | Example | Best For | Mechanism | Limitation | |---|---|---|---|---| | Dopamine agonists | Bromocriptine, pramipexole | Early PD, monotherapy | D2 receptor activation | Dyskinesias, ergot toxicity (bromocriptine) | | AADC inhibitor | Carbidopa + levodopa | All stages | Increase striatal dopamine | Motor fluctuations in advanced PD | | MAO-B inhibitor | Selegiline | Advanced PD adjunct | Reduce dopamine breakdown | Modest symptomatic benefit | | Anticholinergic | Trihexyphenidyl | Tremor-dominant PD | Block muscarinic receptors | Ineffective for bradykinesia |